Stryker (SYK) recently received FDA clearance for its OptaBlate BVN Basivertebral Nerve Ablation System (OptaBlate BVN), a significant milestone in the treatment of chronic vertebrogenic lower back pain. The addition of the OptaBlate BVN to Stryker's pain portfolio expands its advanced pain therapy solutions for patients and represents the intersection of two of the company’s core competencies: radiofrequency ablation technology and vertebral access.As back pain remains one of the most prevalent and debilit ...